Zydus teriparatide
Teriparatide biosimilar developed by Cadila Healthcare (Zydus Lifesciences). Reference product Forsteo (Forteo in the United States).
Brands by market: Brand not published by CDSCO (India) ยท Commercial partner or holder: Zydus Lifesciences
FDAnot listed
EMAnot listed
CDSCOAug 2012permitted
EDEnot listed
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union
Not listed by EMA.
CDSCO
India
Central Drugs Standard Control OrganisationApprovedBrand
Not published by CDSCO (INN only)
Holder or applicant
Cadila Healthcare Ltd
Pathway
Similar Biologic, manufacture and marketing permission
Approved
Aug 2012
Application or permission
MF-207/2012
Indications as licensed
Postmenopausal women with osteoporosis at high risk of fracture
Presentations
Vial and cartridge
Source
S014
EDE
United Arab Emirates
Not listed by EDE.
Chronology
- CDSCOAug 2012CDSCO permission granted
Sources
S014CDSCO, permissions granted in Form 46 and 46A, to 2019 Primary (regulator)
Planning teriparatide biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.